tradingkey.logo

ADMA Biologics Inc

ADMA
View Detailed Chart
14.710USD
+0.190+1.31%
Close 11/10, 16:00ETQuotes delayed by 15 min
3.51BMarket Cap
16.74P/E TTM

ADMA Biologics Inc

14.710
+0.190+1.31%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.31%

5 Days

-4.29%

1 Month

+1.17%

6 Months

-26.38%

Year to Date

-14.23%

1 Year

-34.97%

View Detailed Chart

TradingKey Stock Score of ADMA Biologics Inc

Currency: USD Updated: 2025-11-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

ADMA Biologics Inc's Score

Industry at a Glance

Industry Ranking
30 / 159
Overall Ranking
78 / 4611
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 4 analysts
Buy
Current Rating
27.250
Target Price
+87.67%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

ADMA Biologics Inc Highlights

StrengthsRisks
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 176.77% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Fairly Valued
The company’s latest PE is 16.58, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 215.13M shares, decreasing 10.61% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 0.00 shares of this stock.

ADMA Biologics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

ADMA Biologics Inc Info

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Ticker SymbolADMA
CompanyADMA Biologics Inc
CEOMr. Adam S. Grossman
Websitehttps://www.admabiologics.com/
KeyAI